EHS
EHS

Venclexta Approved for CLL/SLL After 1 Prior Therapy

The FDA granted regular approval to venetoclax (Venclexta, AbbVie/Genentech) in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma, with or without 17p deletion, who have received at least one previous therapy.
EHS
Back to top button